Compare Organon & Co. Common Stock (OGN) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs WD 40 Company — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while WD 40 Company trades at $203.62 (market cap $2.74B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and WD 40 Company pays the higher dividend (2%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and WD 40 Company for 23 Days on average.
| OGN | WDFC | |
|---|---|---|
Market Cap | $3.62B | $2.74B |
Volume | 2,892,999 | 121,880 |
Sector | Health | Basic Materials |
52-Week High | $13.81 | $264.91 |
52-Week Low | $5.70 | $187.52 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $11.04B | $2.80B |
Dividend Yield | 0.58% | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
WDFC trades at $204.41, up 0.8% today, with a bullish technical signal from moving averages and key resistance at $206. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.33, and maintains robust profitability with a 33.22% ROE. Recent news highlights strategic growth initiatives and institutional buying interest.
Outlook is mixed; solid fundamentals and growth strategy support upside, but high valuation (P/E 31.07) and margin pressures from input costs pose risks. Analyst consensus is cautious with 71% hold ratings, indicating tempered expectations despite operational strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
